Select Publications
Conference Papers
, 2019, 'Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy', in Cancer Research, American Association for Cancer Research (AACR), pp. 4754 - 4754, http://dx.doi.org/10.1158/1538-7445.am2019-4754
, 2018, 'Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-1999
, 2017, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo/radio-resistance in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2833
, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways in vitro', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-4005
, 2008, 'Backward probabilistic logic reasoning algorithm for decision problem with conditional event algebra on bayesian networks', in Proceedings of the 7th International Conference on Machine Learning and Cybernetics Icmlc, pp. 1744 - 1749, http://dx.doi.org/10.1109/ICMLC.2008.4620687
, 2008, 'Identification of the potential biomakers for prostate cancer from tears and sera using proteomic methods', in The 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, presented at 13th Annual Proteomics Symposium Erskine Mantra Resort, Lorne , VIC, 08 February 2008 - 10 February 2008
, 2006, 'Control of DU 145 and LNCaP-LN3 prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates', in Annals of Oncology, Oxford Univ Press, Oxford, England, presented at Symposium on targeted anticancer therapies, Amsterdam, 16 March 2006 - 18 March 2006, http://dx.doi.org/10.1093/annonc/mdl921
, 2004, 'In Vitro Targeting of NG2 antigen by 213Bi-9.2.27 radioimmunoconjugate induces cytotoxicity in human uveal melanoma cells', presented at XVI international congress of eye research, 29 August 2004 - 03 September 2004
, 2004, 'Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines and Primary Prostate Cancer Sections for In Vitro Multiple Targeted Alpha Therapy with 213Bi-conjugates.', presented at 95th AACR annual meeting, 27 March 2004 - 31 March 2004
, 2003, '213Bi-PAI2 conjugate selectively induced apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model', presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
, 2003, 'Evaluation of preclinical single and multiple dose toxicity and efficacy of 213Bi-labeled plasminogen activator inhibitor 2 for breast and prostate cancer.', 17 September 2003 - 22 September 2003
, 2003, 'In vitro and in vivo targeted alpha therapy (TAT) of colorectal cancer using monoclonal antibodies c30 and 35A7', presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
, 2003, 'In vitro cytotoxicity of alpha conjugates for human pancreatic cancer cell lines', presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003
, 2003, 'Targeted alpha therapy for human prostate cancer cell lines in vitro using -particle emitter (213Bi)-labeled Herceptin.', presented at 12th International Congress of Radiation Research, 17 September 2003 - 22 September 2003